SPH No. 1 Biochemical & Pharmaceutical

SPH No.1 Biochemical & Pharmaceutical is a major R&D and manufacturing subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., focused on innovative drugs including small molecules, biologics such as monoclonal antibodies and biosimilars, live biotherapeutics/probiotics, and advanced therapies like CAR-T cell therapies and gene therapies. The company has several marketed products in China—including Oncorine (recombinant human adenovirus type 5), Kallidinogenase (urinary), Peifeikang (bifidobacterium triple viable bacteria)—and an extensive pipeline with at least six innovative drugs in pivotal or Phase III studies[4]. It is also advancing CAR-T programs into clinical trials[7][10].